Fosun Pharma Reports 2025 Results: Dual Engines of Innovative Drugs and Globalization Drive High-Quality Growth

Stock News03-24

Fosun Pharma (600196.SH, 02196) has announced its operating results for the 2025 fiscal year. Driven by breakthroughs in innovative R&D and the upgrade of its global system, the company achieved revenue of RMB 41.662 billion, a year-on-year increase of 1.45%. Within this, revenue from innovative drugs amounted to RMB 9.893 billion, up 29.59% year-on-year, while overseas revenue reached RMB 12.977 billion, an increase of 14.87% year-on-year. The dual growth in these two core indicators reinforces the underlying logic of Fosun Pharma's high-quality development. Net profit attributable to owners of the parent company was RMB 3.371 billion, rising 21.69% year-on-year. Net profit attributable to owners of the parent company after deducting non-recurring items was RMB 2.340 billion, an increase of 1.12% year-on-year. Net cash flow generated from operating activities was RMB 5.213 billion, up 16.45% year-on-year, further strengthening the foundation for high-quality growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140550222?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140550222","market":"us","top_or_hot":-1,"title":"Fosun Pharma Reports 2025 Results: Dual Engines of Innovative Drugs and Globalization Drive High-Quality Growth","media":"Stock News","content":"<p>Fosun Pharma (600196.SH, 02196) has announced its operating results for the 2025 fiscal year. Driven by breakthroughs in innovative R&D and the upgrade of its global system, the company achieved revenue of RMB 41.662 billion, a year-on-year increase of 1.45%. Within this, revenue from innovative drugs amounted to RMB 9.893 billion, up 29.59% year-on-year, while overseas revenue reached RMB 12.977 billion, an increase of 14.87% year-on-year. The dual growth in these two core indicators reinforces the underlying logic of Fosun Pharma's high-quality development. Net profit attributable to owners of the parent company was RMB 3.371 billion, rising 21.69% year-on-year. Net profit attributable to owners of the parent company after deducting non-recurring items was RMB 2.340 billion, an increase of 1.12% year-on-year. Net cash flow generated from operating activities was RMB 5.213 billion, up 16.45% year-on-year, further strengthening the foundation for high-quality growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Reports 2025 Results: Dual Engines of Innovative Drugs and Globalization Drive High-Quality Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Reports 2025 Results: Dual Engines of Innovative Drugs and Globalization Drive High-Quality Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-24 19:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fosun Pharma (600196.SH, 02196) has announced its operating results for the 2025 fiscal year. Driven by breakthroughs in innovative R&D and the upgrade of its global system, the company achieved revenue of RMB 41.662 billion, a year-on-year increase of 1.45%. Within this, revenue from innovative drugs amounted to RMB 9.893 billion, up 29.59% year-on-year, while overseas revenue reached RMB 12.977 billion, an increase of 14.87% year-on-year. The dual growth in these two core indicators reinforces the underlying logic of Fosun Pharma's high-quality development. Net profit attributable to owners of the parent company was RMB 3.371 billion, rising 21.69% year-on-year. Net profit attributable to owners of the parent company after deducting non-recurring items was RMB 2.340 billion, an increase of 1.12% year-on-year. Net cash flow generated from operating activities was RMB 5.213 billion, up 16.45% year-on-year, further strengthening the foundation for high-quality growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0187","symbol_name":"一线龙头","start_time":0,"source_url":"","article_id":"1140550222","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140550222","pubTimestamp":1774351459,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Fosun Pharma (600196.SH, 02196) has announced its operating results for the 2025 fiscal year. Driven by breakthroughs in innovative R&D and the upgrade of its global system, the company achieved...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","600196":"复星医药","BK0187":"一线龙头","BK0028":"国家队","06978":"永泰生物-B","02196":"复星医药","BK1191":"制药","BK1161":"生物科技","BK1593":"医美概念股","BK0175":"白马股","BK0060":"抗癌","BK1515":"抗疫概念","BK0196":"行业龙头","BK1574":"生物医药B类股","BK0239":"医药制造","BK0096":"民营医院","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"复星医药公布2025业绩：创新药和全球化双引擎驱动高质量增长","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"600196":1,"06978":1,"02196":1},"content_text":"Fosun Pharma (600196.SH, 02196) has announced its operating results for the 2025 fiscal year. Driven by breakthroughs in innovative R&D and the upgrade of its global system, the company achieved revenue of RMB 41.662 billion, a year-on-year increase of 1.45%. Within this, revenue from innovative drugs amounted to RMB 9.893 billion, up 29.59% year-on-year, while overseas revenue reached RMB 12.977 billion, an increase of 14.87% year-on-year. The dual growth in these two core indicators reinforces the underlying logic of Fosun Pharma's high-quality development. Net profit attributable to owners of the parent company was RMB 3.371 billion, rising 21.69% year-on-year. Net profit attributable to owners of the parent company after deducting non-recurring items was RMB 2.340 billion, an increase of 1.12% year-on-year. Net cash flow generated from operating activities was RMB 5.213 billion, up 16.45% year-on-year, further strengthening the foundation for high-quality growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140550222","isCrawlerRequest":true}